Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Psychemedics Corporation Launches New Hair Alcohol Test

PMDI
Psychemedics Corporation Launches New Hair Alcohol Test

World's largest hair analysis drug testing company launches new test that determines consumption levels of alcohol by measuring EtG in hair.

ACTON, Mass., July 8, 2013 /PRNewswire/ -- Psychemedics Corporation (NASDAQ:PMD), hair testing pioneer and global leader for over twenty-five years, announced the launch of its hair alcohol test – a test that measures average alcohol consumption over a period of approximately three months, indicates the level of alcohol use during that time period, and can provide a behavioral indication of excessive use.

Alcohol is the most abused substance in the world, and excessive use poses serious health and safety issues to society. In other regions of the world, this test has been used effectively in the courts, corporate alcohol screening programs, and in monitoring medical issues and probation compliance.  Psychemedics' new hair alcohol test provides answers about alcohol abuse and can be an indicator of those dependent on alcohol.

The test measures the amount of ethyl glucuronide (EtG) in the hair – a trace metabolite of ethanol and a direct alcohol biomarker – and follows the guidelines determined by the World Health Organization in association with the Society of Hair Testing for measuring consumption.

This non-invasive testing procedure uses a small sample of hair that is easily collected and shipped.  All work is done by Psychemedics' College of American Pathologists (CAP) and ISO/IEC 17025:2005  certified laboratory.

Advancing The Science Of Hair Testing

Psychemedics  established its technological and market leadership position in 1987 with the development of the first hair test to detect drugs of abuse. Continued advancement in the science of hair testing is critical to Psychemedics, and this new alcohol test provides clients with another method to identify substance abuse.

Raymond C. Kubacki, Chairman and CEO stated, "We are excited to announce the availability of this new hair alcohol test. Our company has, for over twenty-five years, offered the most effective hair testing technology based upon scientifically validated drug testing methods. After many years of investing time and research into developing a hair alcohol test, we are proud to now provide the market with a reliable test to measure alcohol consumption over a period of time."

About Psychemedics Corporation

Psychemedics Corporation is the world's largest provider of hair testing for drugs of abuse and has been successfully operating for over 25 years.  Thousands of corporations rely on the proprietary Psychemedics drug testing services.  Psychemedics's clients include over 10% of the Fortune 500, some of the largest police departments in America, six Federal Reserve Banks, and schools. 

For more information, visit the Psychemedics Corporation website at www.psychemedics.com.

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning technological changes, technological advantages, regulatory matters, implementation of new testing procedures and processes, research and development, future business and marketing strategies may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with implementation of new testing procedures and methodologies including training, personnel changes, changes in supplier relationships, customer contract provisions and customer relationships, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Contact: 

Raymond C. Kubacki 


Chairman, President and CEO 


(978) 206-8220

SOURCE Psychemedics Corporation